Down’s syndrome with dementia
The antibody BAN2401, which is now being clinically evaluated for the treatment of Alzheimer’s disease, can potentially also be used for other indications such as Down’s syndrome with dementia, as most of these patients develop dementia pathology at around 40 years of age.
Traumatic brain injury
In 2015, BioArctic applied for patents for the antibodies BAN2401 and its backup for the treatment of Traumatic brain injury (TBI). Some of these patients develop dementia with Alzheimer pathology after the injury.